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Aims Carotid–femoral pulse wave velocity (PWV), a direct measure of aortic stiffness, has become increasingly important
for total cardiovascular (CV) risk estimation. Its application as a routine tool for clinical patient evaluation has been
hampered by the absence of reference values. The aim of the present study is to establish reference and normal
values for PWV based on a large European population.
Methods
and results
We gathered data from 16 867 subjects and patients from 13 different centres across eight European countries, in
which PWV and basic clinical parameters were measured. Of these, 11 092 individuals were free from overt CV
disease, non-diabetic and untreated by either anti-hypertensive or lipid-lowering drugs and constituted the reference
value population, of which the subset with optimal/normal blood pressures (BPs) (n ¼ 1455) is the normal value
population. Prior to data pooling, PWV values were converted to a common standard using established conversion
formulae. Subjects were categorized by age decade and further subdivided according to BP categories. Pulse wave
velocity increased with age and BP category; the increase with age being more pronounced for higher BP categories
and the increase with BP being more important for older subjects. The distribution of PWV with age and BP category
is described and reference values for PWV are established. Normal values are proposed based on the PWV values
observed in the non-hypertensive subpopulation who had no additional CV risk factors.
Conclusion The present study is the ﬁrst to establish reference and normal values for PWV, combining a sizeable European popu-
lation after standardizing results for different methods of PWV measurement.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Among markers of arterial disease, arterial stiffness has proven to
be an important parameter for the assessment of cardiovascular
(CV) risk. From the different methods to assess arterial stiffness,
1
carotid to femoral pulse wave velocity (PWV) has emerged as the
gold standard method because of its relative ease in determination,
its perceived reliability,
2,3 and most importantly because of the
large body of evidence demonstrating its association with incident
CV disease (CVD), independently of traditional risk factors and in
various populations.
2,4–10 Increasingly, arterial stiffness measures,
and PWV in particular, are included both in the routine clinical
assessment of patients and within the framework of large-scale
clinical studies, as illustrated by their inclusion in the 2007 ESH/
ESC guidelines for the management of hypertension.
3
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doi:10.1093/eurheartj/ehq165In spite of its emergence as the gold standard method for the
assessment of central arterial stiffness, a wider implementation of
PWV into clinical practice is hampered by the lack of established
reference values based on a large population and the absence of
a standardization of methodology for PWV assessment. The
ﬁxed threshold value (12 m/s) proposed in the 2007 ESH/ESC
hypertension guidelines
3 was based on published epidemiological
studies but could not take into account the multiple factors inﬂu-
encing PWV. Two groups have recently published normative data,
but one related only to a speciﬁc elderly population
11 and the
other concerned only one methodology.
12 It has been proven
that important differences in absolute PWV values exist between
methodologies
13–15 and/or between populations.
16 On the other
hand, many risk factors have been shown to inﬂuence PWV in
small-scale studies and may be confounded by differences in age
and blood pressure (BP) level.
17 Thus, establishment of reference
value for PWV must standardize methodology and must be
based on the wider possible population, taking into account the
inﬂuence of major CV risk factors on PWV. Another problem
with PWV is its strong dependence on age and BP.
12,17 It is
unclear now whether reference values must be (or not) deter-
mined as a function of age and BP, but it is important to take
them into account. For example, subjects might be classiﬁed at
higher risk than others in a certain age group, even when PWV
does not reach the 12 m/s threshold. Similarly, knowing how
PWV distributes along classes of BP would help to identify individ-
uals with excessively high PWV or preserved PWV, which may be
of importance for modalities of treatment.
18 Establishing normality
is not equivalent to providing the range of values observed in a
general population, this is why we distinguish between normal
values, in a population with no CV risk factor (apart from age
and sex), and reference values, which are closer to a population-
based distribution of PWV.
With ﬁnancial support from the French Ministry of Research
(Agence Nationale pour la Recherche) endorsed by the European
Network for Non-Invasive Investigation of Large Arteries, the
Reference Values for Arterial Stiffness’ Collaboration aims at build-
ing a large database combining existing clinical and arterial stiffness
data from participating centres across Europe.
19 The objectives of
the present study were to (i) establish ‘normal’ values of
carotid-to-femoral PWV in a population with no CV risk factor
and (ii) to propose ‘reference’ value in a population with various
risk factors, according to age and BP categories. For this
purpose, it was necessary to ﬁrst identify the main determinants
of PWV and to standardize the expression of PWV.
Methods
Study population
The population retained for the present analysis is a subgroup of the
‘Reference Values for Arterial Stiffness’ Collaboration database’,
described previously.
19 Brieﬂy, this database contains patients and sub-
jects having had measurements of arterial stiffness (PWV or local stiff-
ness measures obtained from ultrasound echotracking) and/or
measurements of central pressure, together with a full medical
history on record. These were provided by 13 centres distributed
across eight European countries (see Appendix for the list of
contributing centres). Inclusion criteria also included the availability
of a full set of documentation regarding the protocol and measurement
techniques used for the assessment of stiffness parameters.
Subjects were excluded from the present analysis if PWV measure-
ment was unavailable, if they had an identiﬁed genetic cause of hyper-
tension or secondary hypertension, or had overt CVD. Diabetic
patients (either treated or untreated) and patients treated for hyper-
tension or dyslipidaemia were also excluded.
Subject data included vital parameters, BPs, and the recording of any
relevant CV risk factor, CVD, or treatment at the time of measure-
ment. Ethnicity was not reported in all data sets; however, subjects
other than Caucasians were a small minority. Subjects were further
categorized (Figure 1) according to the presence of additional CV
risk factors (gender, dyslipidaemia, or current smoking). Dyslipidaemia
was deﬁned as total cholesterol .5.0 mmol/L, HDL cholesterol
,1.0 mmol/L for men and ,1.2 mmol/L for women, LDL cholesterol
.3.0 mmol/L, or triglycerides .1.7 mmol/L. Blood pressure was
measured according to the procedures of each participating centre.
The values of BP are those obtained during the measurement of
PWV. Methods for BP measurement may vary with time and within
centres. Automatic oscillometric devices were used in more than
80% of subjects. Mean BP (MBP) was calculated from systolic BP
(SBP) and diastolic BP (DBP) as MBP ¼ DBP + 0.4(SBP 2 DBP).
Threshold values for CV risk factors were chosen according to the
2007 ESC/ESH hypertension guidelines.
3
Study populations
A ‘normal’ population was deﬁned as subjects having optimal or
normal BP values and no additional CV risk factors. We further
studied the inﬂuence of CV risk factors on PWV. On the basis of
this analysis, we deﬁned a ‘reference’ value population as subjects or
patients of both sexes, presenting CV risk factors which had been
shown to have no independent inﬂuence on PWV values.
For normal and reference values, the population was categorized
according to the age decade (,30, 30–39, 40–49, 50–59, 60–69,
and ≥70 years) and BP category
3 (reference population only:
optimal, i.e. ,120/80; normal, i.e. ≥120/80 and ,130/85; high
normal, i.e. ≥130/85 and ,140/90; Grade I hypertension, i.e. ≥140/
90 and ,160/100; and Grade II/III hypertension, i.e. ≥160/100 mmHg).
Pulse wave velocity measurement:
methodological considerations
Pulse wave velocity values depend on both the algorithm used for
detecting the so-called ‘foot of the wave’ at the measurement sites
and path length measurement. An overview of the different techniques
was recently published,
20 and the list of techniques and devices applied
in the different centres is provided in Appendix. We had to standardize
the calculation of PWV.
Transit times are assessed as the time difference between two
characteristic points on carotid and femoral waveforms. The character-
istic points chosen are dependent on the type of waveform (ﬂow,
pressure, or diameter distension) and the algorithm used for its detec-
tion. The two most popular algorithms are (i) the intersecting tangent
algorithm (Sphygmocor
w system and for manual identiﬁcation) and (ii)
the point of maximal upstroke during systole (as used in the Com-
plior
w system). Different algorithms applied on the same waveforms
can lead to differences in measured PWV values of 5–15%.
13 Since
the point of maximal upstroke has been shown to underestimate
PWV, especially when the rise time of the waveform is low,
13 we
chose to standardize transit time on the intersecting tangent algorithm.
To convert maximal upstroke transit times into the intersecting
Determinants of PVW in healthy people 2339tangent algorithm, we used the relationship previously found by Millas-
seau et al.:
13
Dtintersectingtangent =
Dtmaxmalupstroke − 14.96
0.8486
(ms)( 1)
Pulse wave velocity values are also markedly dependent on the
carotid–femoral pathway measurement. This pathway can either be
the direct distance measured between the carotid and femoral
measurement sites, or the distance obtained by subtracting the
carotid measurement site to sternal notch distance from the sternal
notch to femoral measurement site distance. Differences in path
length alone can lead to differences in PWV values of up to
30%.
21,22 Equations to convert between these path length deﬁnitions
with good precision were recently published:
23
xdirect = 0.45xsubtracted + 0.21 × height + 0.08 (m)( 2)
xsubtracted = 1.04xdirect − 0.11 × height − 0.02 (m)( 3)
Because participating centres used different methods to measure
PWV (see Table A1), path length values had to be standardized. The
bulk of the data in the reference value database consists of PWV cal-
culated using the direct path length. Subtracted path lengths were
therefore standardized into direct path lengths using Eq. (2).
However, as the use of direct distance (i.e. measured over the body
surface) leads to overestimation of real PWV [using magnetic reson-
ance imaging (MRI) or invasive measurements], we used a scaling
Figure 1 Flowchart describing the selection and categorization of subjects from the reference value database for the present analysis. PWV,
pulse wave velocity; CVD, cardiovascular disease; BP, blood pressure.
P. Boutouyrie and S.J. Vermeersch 2340factor of 0.8 derived from Sugawara et al.
24 and Weber et al.
15 to
convert PWV obtained using direct distances to ‘real’ PWV.
PWV = 0.8
xdirect
Dt
m
s

(4)
In what follows, PWV is calculated using the intersecting tangent
algorithm and the direct carotid to femoral path length, and then
rescaled to real PWV using Eq. (4). Tables using PWV values based
on the intersecting tangent algorithm and direct or subtracted dis-
tances are supplied as Supplementary material online.
Statistical analyses
All statistical analyses were performed using R version 2.9.1.
25 Values
reported are mean (standard deviation). The threshold for statistical
signiﬁcance was chosen to be P ¼ 0.05 unless stated otherwise. The
inﬂuence of CV risk factors and gender on PWV was examined by per-
forming analysis of covariance, before and after adjustment for age and
MBP. Pulse wave velocity values per category are represented as mean
(standard deviation) and median (10th to 90th percentile). Corre-
lations were assessed using regression analyses.
Results
Study population
A ﬂowchart describing how subjects were selected from the com-
plete reference value database and then further subdivided accord-
ing to the presence of CV risk factors is presented in Figure 1. The
complete reference value database contains data from 24 484 sub-
jects and patients. The number of subjects included per centre is
listed in Appendix. Pulse wave velocity and relevant clinical data
were present in 16 867 subjects. Of those, 1165 subjects were
excluded due to the presence of overt CVD. An additional 3578
subjects were excluded because of treatment for hypertension
or dyslipidaemia and ﬁnally 1032 subjects were excluded for dia-
betes (treated or not), resulting in a study population of 11 092
subjects. This population represents the ‘reference value popu-
lation’. Demographic parameters and clinical data of the ‘reference
value’ and ‘normal value’ population are summarized in Table 1.
The number of subjects included in each category of age and BP
is listed in Table 2.
Cardiovascular risk factors and observed
pulse wave velocity
Table 3 summarizes the effects of different CV risk factors on PWV
values. Although PWV was markedly higher in males, dyslipidaemics,
and smokers, the presence of these CV risk factors was also
accompanied by marked differences in age and BP. After correction
for quadratic age (a + b × age + c × age
2) and MBP, there was no
signiﬁcant inﬂuence of smoking status or dyslipidaemia and negligible
inﬂuence of gender on PWV (,0.1 m/s difference, P ¼ 0.04).
Although PWV was signiﬁcantly dependent on heart rate, further
adjustment on sex, quadratic age, and MBP reduced its residual
...............................................................................................................................................................................
Table 1 Description of general clinical parameters of the reference value and normal value populations
Parameter PWV database
(16 867 subjects)
Reference value population
(11 092 subjects)
Normal value population
(1455 subjects)
Age (years) 55 (17) 50 (17) 33 (16)
Age range (years) (15–97) (15–97) (15–85)
Gender (M/F) 8753/8114 5520/5572 600/855
Weight (kg) 74.4 (14.8) 73.0 (14.3) 66.8 (11.9)
Height (m) 1.69 (0.09) 1.70 (0.09) 1.71 (0.09)
SBP (mmHg) 135 (21) 130 (19) 114 (9)
DBP (mmHg) 79 (12) 78 (12) 69 (7)
MBP (mmHg) 102 (14) 99 (13) 87 (7)
PP (mmHg) 56 (16) 52 (14) 45 (8)
Total cholesterol (mmol/L) 5.5 (1.2) 5.5 (1.2) 4.1 (0.6)
HDL cholesterol (mmol/L) 1.5 (0.4) 1.5 (0.4) 1.6 (0.3)
LDL cholesterol (mmol/L) 3.3 (1.1) 3.3 (1.1) 2.2 (0.5)
Triglycerides (mmol/L) 1.3 (0.9) 1.2 (0.8) 0.8 (0.3)
Glycaemia (mmol/L) 5.4 (1.3) 5.0 (0.6) 4.8 (0.6)
Smoking [# (%)] 3761 (22) 2634 (24) —
Dyslipidaemia [# (%)] 13 284 (79) 8441 (76) —
Hypertension [# (%)] 6,818 (40) 3431 (31) —
Diabetes [# (%)] 1223 (7) — —
Treated hypertension [# (%)] 4149 (25) — —
Treated lipids [# (%)] 1879 (11) — —
Treated diabetes [# (%)] 616 (4) — —
SBP, DPB, PP, and MBP signify systolic, diastolic, pulse, and mean blood pressure, respectively. PWV, pulse wave velocity; HDL and LDL, mean high- and low-density lipoproteins,
respectively.
Determinants of PVW in healthy people 2341inﬂuence on PWV which was very small (standardized coefﬁcient for
heart rate is 1/4th the one for MBP and 1/10th the one for age).
Diabetic subjects and subjects treated for hypertension and dys-
lipidaemia had signiﬁcantly elevated PWV values, compared with
untreated patients, even after correction for age and MBP (data
not shown). This is why we decided not to include these patients.
Since gender, smoking, and lipid status have no independent
inﬂuence on PWV after correction for quadratic age and BP
differences, we deﬁned the reference value population as including
all untreated (i.e. with no anti-hypertensive or lipid-lowering
agents) non-diabetic subjects.
Normal and reference values for pulse
wave velocity
Normal values are presented in Table 4 and Figure 2. Subjects with
optimal or normal BP and no additional CV risk factors had the
lowest values of PWV and showed the smallest increase in PWV
with age. It can be noted from Figure 3 and Table 5 that subjects
with normal BP values had already elevated PWV values, compared
with subjects with optimal BP, together with an increased age/
PWV coefﬁcient. The scattering of data is very small for the ﬁrst
age categories and increases with age. Outliers were more fre-
quent at older ages (Figure 2).
.................................................................................
...............................................................................................................................................................................
Table 2 Number of subjects included in each of the age and blood pressure categories in the reference values
population (11 092 subjects)
Age category (years) Optimal Normal Blood pressure group
High normal Grade I HT Grade II/III HT
,30 896 417 220 96 40
30–39 315 245 184 189 109
40–49 822 562 385 325 167
50–59 514 519 434 490 238
60–69 414 509 485 648 289
≥70 163 244 333 535 305
HT, hypertension.
.............................. ..............................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 3 Inﬂuence of gender and major cardiovascular risk factors on pulse wave velocity, before and after adjustment
on quadratic age and mean blood pressure
Cardiovascular risk factor # subjects Mean age (years) MBP (mmHg) Pulse wave velocity
before adjustment
Pulse wave velocity
after adjustment
Mean (m/s) P-value Mean (m/s) P-value
Gender
F 1127 37 91 7.4 ,0.001 7.7 0.04
M 1080 39 97 8.2 7.8
Dyslipidaemia
No 2207 38 94 7.8 ,0.001 8.9 0.68
Yes 6251 54 101 9.3 8.9
Current smoker
No 2207 38 94 7.8 0.04 7.8 0.84
Yes 444 43 96 8.0 7.8
MBP, mean blood pressure.
................................................................................
Table 4 Distribution of pulse wave velocity (m/s)
according to the age category in the normal values
population (1455 subjects)
Age category (years) Mean (+ + + + +2 SD) Median (10–90 pc)
,30 6.2 (4.7–7.6) 6.1 (5.3–7.1)
30–39 6.5 (3.8–9.2) 6.4 (5.2–8.0)
40–49 7.2 (4.6–9.8) 6.9 (5.9–8.6)
50–59 8.3 (4.5–12.1) 8.1 (6.3–10.0)
60–69 10.3 (5.5–15.0) 9.7 (7.9–13.1)
≥70 10.9 (5.5–16.3) 10.6 (8.0–14.6)
SD, standard deviation; 10 pc, the upper limit of the 10th percentile; 90 pc, the
lower limit of the 90th percentile.
P. Boutouyrie and S.J. Vermeersch 2342Reference values for PWV are illustrated in Figure 3, showing a
graphical representation of PWV values according to age and BP
categories. Pulse wave velocity values and distributions in each of
the categories are described in Table 5.
Pulse wave velocity increased both with increasing age and BP
levels in the reference value population. Within all BP categories,
quadratic regression offered the best ﬁt to the observed data.
Regression equations within each of the BP categories are summar-
izedinTable6.TheincreaseinPWVwithagewasmorepronounced
whenthelevelsofBPincreased(Figure4,top),theﬁtwithafullquad-
ratic equation (a + b × age + c × age
2) providing better values of
R
2 than linear ﬁt by 4–6%. The enhanced inﬂuence of ageing with
high BP was gradual: the coefﬁcient c for square-age increases by
1.5-fold (the linear coefﬁcient being negligible), and the intercept
increased by 0.6 m/s between optimal BP and Grade I hypertension.
For Grade II/III hypertension, the linear term became obvious and
accelerated effect of age was visible in Figure 4, top. Likewise, the
increase in PWV with MBP was more pronounced as the subjects
were older (Figure 4, bottom). Here, the best ﬁt between MBP and
PWV was linear (Table 6). The slope of the PWV/MBP relationship
increased gradually with increasing categories of age, up to 1.5-fold
higher in older subjects than in younger subjects. All correlations
(PWV and age, PWV and MBP) were highly signiﬁcant (P , 0.001).
Models including all interaction terms show that MBP is only signiﬁ-
cantly associated with PWV through its interaction with age and
square-age in the reference population, whereas it has a small, but
signiﬁcant independent association with PWV in the normal popu-
lation (see Supplementary material online).
Figure 2 Normal values for pulse wave velocity: average according to age (1455 subjects). Boxes contain 50% of the data and bars contain
the remainder; horizontal lines indicate medians and the circle indicates outliers.
Figure 3 Reference values for pulse wave velocity (PWV): mean values according to age and blood pressure (BP) categories (11 092 sub-
jects). HT, hypertension.
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The main result of this study is the establishment of normal and
reference values for PWV based on an extensive data set obtained
from 13 centres distributed across Europe. This is the ﬁrst study
taking into account different methodological approaches for the
determination of PWV by applying previously established conver-
sion equations for path lengths and transit times. Reference
values are presented per age decade and BP category. These
normal and reference values represent a critical step in the
implementation of PWV as a clinical tool for detecting subclinical
organ damage in routine patient workup.
Despite the independent value of PWV as a measure of aortic
stiffness and, vitally, of prognosis, its use has been limited
without reliable reference values. Standardization is mandatory
for generalizing any diagnostic test, be it biological
26 or morpho-
logical.
27 In the case of PWV, most of the necessity for standard-
ization is purely methodological. Pulse wave velocity values
........................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 5 Distribution of pulse wave velocity (PWV) values (m/s) in the reference value population (11 092 subjects)
according to age and blood pressure category
Age category (years) Blood pressure category
Optimal Normal High normal Grade I HT Grade II/III HT
PWV as mean (+2 SD)
,30 6.1 (4.6–7.5) 6.6 (4.9–8.2) 6.8 (5.1–8.5) 7.4 (4.6–10.1) 7.7 (4.4–11.0)
30–39 6.6 (4.4–8.9) 6.8 (4.2–9.4) 7.1 (4.5–9.7) 7.3 (4.0–10.7) 8.2 (3.3–13.0)
40–49 7.0 (4.5–9.6) 7.5 (5.1–10.0) 7.9 (5.2–10.7) 8.6 (5.1–12.0) 9.8 (3.8–15.7)
50–59 7.6 (4.8–10.5) 8.4 (5.1–11.7) 8.8 (4.8–12.8) 9.6 (4.9–14.3) 10.5 (4.1–16.8)
60–69 9.1 (5.2–12.9) 9.7 (5.7–13.6) 10.3 (5.5–15.1) 11.1 (6.1–16.2) 12.2 (5.7–18.6)
≥70 10.4 (5.2–15.6) 11.7 (6.0–17.5) 11.8 (5.7–17.9) 12.9 (6.9–18.9) 14.0 (7.4–20.6)
PWV as median (10–90 pc)
,30 6.0 (5.2–7.0) 6.4 (5.7–7.5) 6.7 (5.8–7.9) 7.2 (5.7–9.3) 7.6 (5.9–9.9)
30–39 6.5 (5.4–7.9) 6.7 (5.3–8.2) 7.0 (5.5–8.8) 7.2 (5.5–9.3) 7.6 (5.8–11.2)
40–49 6.8 (5.8–8.5) 7.4 (6.2–9.0) 7.7 (6.5–9.5) 8.1 (6.8–10.8) 9.2 (7.1–13.2)
50–59 7.5 (6.2–9.2) 8.1 (6.7–10.4) 8.4 (7.0–11.3) 9.2 (7.2–12.5) 9.7 (7.4–14.9)
60–69 8.7 (7.0–11.4) 9.3 (7.6–12.2) 9.8 (7.9–13.2) 10.7 (8.4–14.1) 12.0 (8.5–16.5)
≥70 10.1 (7.6–13.8) 11.1 (8.6–15.5) 11.2 (8.6–15.8) 12.7 (9.3–16.7) 13.5 (10.3–18.2)
SD, standard deviation, 10 pc, the upper limit of the 10th percentile, 90 pc, the lower limit of the 90th percentile; HT, hypertension.
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 6 Regression equations for pulse wave velocity vs. age (top) and mean blood pressure (bottom) according to
blood pressure category (top) and age category (bottom) in the reference value population (11 092 subjects)
PWV ∼ age 1 age
2 R
2
BP category
Optimal PWV ¼ 0.000 × age + 0.83 × 10
23 × age
2 + 5.55 0.46
Normal PWV ¼ 0.000 × age + 0.99 × 10
23 × age
2 + 5.69 0.47
High normal PWV ¼ 0.000 × age + 1.05 × 10
23 × age
2 + 5.91 0.41
Grade I HT PWV ¼ 0.000 × age + 1.18 × 10
23 × age
2 + 6.17 0.39
Grade II/III HT PWV ¼ 0.044 × age + 0.85 × 10
23 × age
2 + 5.73 0.31
PWV ∼ MBP R
2
Age category (years)
,30 PWV ¼ 0.0472 × MBP + 2.20 0.26
30–39 PWV ¼ 0.0423 × MBP + 2.20 0.13
40–49 PWV ¼ 0.0646 × MBP + 1.41 0.23
50–59 PWV ¼ 0.0731 × MBP + 1.35 0.17
60–69 PWV ¼ 0.0715 × MBP + 3.16 0.13
≥70 PWV ¼ 0.0676 × MBP + 5.46 0.07
Linear coefﬁcient for age marked 0.00 means ,10e–10. All R
2 are highly signiﬁcant (P , 0.001).
P. Boutouyrie and S.J. Vermeersch 2344obtained using different deﬁnitions, while yielding the same type of
information for a group of patients, are not readily comparable
between groups. This has certainly hampered establishing refer-
ence values, as this typically requires the pooling of data across
different centres in order to acquire a sufﬁciently large set of
data. Efforts at establishing reference values have previously been
made, but are usually limited by the size and speciﬁcity of the
population,
11 yielding results that are only valid in these speciﬁc
populations. More importantly, values previously reported have
always been limited to a single PWV methodology,
12 restricting
their applicability to speciﬁc measurement protocols or devices.
The Reference Values for Arterial Stiffness’ Collaboration’s data-
base contains data obtained with a range of techniques representa-
tive of the currently used systems. In the present paper, we used
previously published conversion equations for distance and transit
time measurements to display the data in a uniform fashion. A
majoraimherewastounifythemethodologyandproposeanappro-
priatewaytoexpressPWV.Fortransittimes, wechosedetectionof
the foot of the waveform using an algorithm based on intersecting
tangents. This choice was motivated by several reasons. Algorithms
fortransittimedeterminationhavepreviouslybeencompared,
13and
althoughallalgorithmsprovideproportionalresults,theintersecting
tangent algorithm was found to be the most reliable. For distance
measurements, the ideal choice is less clear-cut. Physiologically,
the subtracted distance more closely resembles invasive
values,
14,15,24,28,29 as it accounts for the time a wave takes to travel
over arterial lengths from the heart to the carotid measurement
site. Despite this, the subtracted distance still differs from the MRI
gold standard.
15,24 However, the subtracted distance requires two
distance measurements, whereas only one measure is enough for
direct measurement. Combining two measurements adds more
complexity, with extra inaccuracies due to the imprecision of
measurement (typically by tape measure or baby rod).
23 The bulk
of epidemiological PWV data available has used direct distance for
PWV calculation. These arguments have recently been discussed
in more depth.
21 For these reasons, we chose to express PWV
Figure 4 (Top) Pulse wave velocity (PWV) vs. age in the reference value population (11 092 subjects). Regression lines denote the results of
regression on age
2 for different blood pressure (BP) categories. (Bottom) Pulse wave velocity vs. mean blood pressure (MBP) in the reference
value population (11 092 subjects). Regression lines denote the results of linear regression on mean blood pressure for different age categories.
HT, hypertension; BP, blood pressure.
Determinants of PVW in healthy people 2345valueshereusingdirectdistanceandintersectingtangent,andfurther
calibratedthevaluestodirect‘MRI’valuesbyusingascalingfactorof
0.8, as established previously
24 [Eq. (4)].
The PWV data in the reference value database can be rep-
resented in different ways. For practical use, the presentation
chosen needs to take into account the pathophysiological features
affecting PWV. Arterial stiffness increases with age and BP; as these
are the major determinants of PWV, its values are presented by
age and BP categories, providing a large number of subjects
within each category allowing reliable estimates.
Pulse wave velocity at any age is linearly related to BPs and
symetrically at any BP level is dependent on the quadratic age.
The slope of the relation between age (and MBP) and PWV
increases by 1.5-fold between the younger/lower BP and the
elderly/higher BP. Although this relationship has been known for
nearly a century,
30 our results show that the increase in PWV
with BP is not simply attributable to the increase in BP with age,
conﬁrming previous observations.
12 The effect of age is empha-
sized in the presence of high BP. It is noteworthy that the inter-
individual difference in PWV for a given age and BP value is
much larger than the inter-class difference. This proves that
PWV measurement includes additional information than the one
provided by age or CV risk factors, as recently emphasized.
17
Other classical risk factors potentially inﬂuencing PWV refer-
ence values were then evaluated in subsets of the whole popu-
lation before and after adjustment on age and MBP. A
comparison of the raw and adjusted mean PWV in Table 3
shows that apparent differences between men and women,
smokers and non-smokers, and dyslipidaemic and normolipaemic
subjects were virtually entirely accounted for by different age
and BP levels. After correction for quadratic age and BP,
smoking and lipid status did not signiﬁcantly inﬂuence PWV, and
gender differences were negligible (though still signiﬁcant
because of the size of the sample). The difference is ,0.1 m/s,
which is small regarding the precision of the technique. Anti-
hypertensive and lipid-lowering treatments and diabetic status
did however inﬂuence PWV beyond effects of age and BP, thus
these patients were excluded from the ﬁnal analysis.
It is important to discriminate between ‘normal’ and ‘reference’
values. The former supposedly supplies a normal (physiological)
range. The latter expresses the range in a population selected to
have no overt CVD. However, these two sets of values (normal
and reference) are not super-imposable. Here, normal values
were established in subjects with optimal or normal BP and no
additional identiﬁed CV risk factors. The values of PWV were
lower in this group, by comparison with any other, and the depen-
dence on age was the weakest. The scattering of data increased
with age, outliers with elevated PWV being more numerous at
older age. The overlap of PWV values between younger and
older people was large, perhaps because many CV risk factors
were not quantiﬁable in the database (among them, psychological
stress, family history of CVD, etc.). In the absence of any CV risk
factors, the increase in PWV with age might even be smaller.
The role of age in presenting normal and reference values needs
careful consideration. As for BP,
3 it is not immediately clear
whether normality should be deﬁned according to age. For BP, it
has proved to be wrong to accept that it should increase
physiologically with age
31,32 and ﬁxed thresholds, regardless of age,
have since been established. Once such thresholds were used,
however, it became apparent that a large fraction of the elderly
population had isolated systolic hypertension.
26 Similarly, an impor-
tant consequence of using a ﬁxed threshold of PWV is that even if
one ‘corrected’ for normal ageing, a majorityofelderlyor hyperten-
sive subjects would have elevated PWV values. Examining Figure 3
(Table 5), a 9.6 m/s threshold value for PWV (12 m/s with directly
measured distance), according to the ESC/ESH guidelines, would
mean that on average, over half the population over 60 years old
are at risk. This is similar to what is observed with the prevalence
of systolic hypertension in the elderly. Blood pressure-lowering
drugs improve outcome in hypertensive patients and some of
these drugs also lower PWV. However, although the proposed
ﬁxed cut-off value of 9.6 m/s (12 m/s with directly measured dis-
tance) is supported by outcome data, evidence for successful inter-
ventiononPWVisnotyetavailablesothatitssurrogatevaluehasnot
yet been established. How the reference value data should be used
to select and stratify patients (age/MBP adjusted or not, value of
centile, etc.) needs to be addressed in future works.
On the basis of the distribution of PWV within each age and BP
category, it is now possible to identify those people at higher risk
than others in a certain age group and represent at which percentile
of reference (or normal) population an individual subject stands.
Limitations
This study is cross-sectional. Although it provides accurate PWV
valuesinalargeaggregateEuropeanpopulation,itprovidesnoinfor-
mation about the evolution of PWVover time and we could not put
in an evidence-tracking phenomenon. Secondly, at present, the
reference value database does not contain outcome data, although
theyareavailablefrommanycomponentstudies.Whethertherefer-
encevaluesshouldbeusedascut-offvaluesfortreatmentremainsto
be discussed. Thirdly, differences in techniques were encountered
and compensated for. Even after full adjustment, differences
between algorithm and path length were blunted, but not totally
abolished. Because of the strong ‘centre/technique’ interaction, we
could not solve the question whether this residual difference
resulted from a centre effect or a suboptimal standardization. In
the same line, it remains differences in PWV between centres even
after full compensation and adjustment (mean difference 0+
0.59 m/s, range 20.9 to 0.8 m/s) which could not be compensated
for. Whether these difference reﬂect geographical differences or
unattended methodological issues remains to be determined.
Togetherwiththelargetimespanofrecruitment,thiscouldincrease
the scattering of the reference values provided, but on the other
hand, it also improves the external validity of our results.
In conclusion, the present study provides reference values for
PWV based on a large European population, using standardized
methodology. The data presented here allow identiﬁcation of
people in whom PWV is abnormal and who might warrant more
intensive follow-up.
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